What is the current Liver Diseases Treatment market size?

The Liver Diseases Treatment market size was valued at USD 12.8 billion in 2023, driven by rising prevalence of chronic liver diseases and advanced therapeutic innovations.

What is the projected growth rate for the market?

The market is forecasted to grow at a CAGR of 7.3% from 2024 to 2031, with a total value expected to exceed USD 24.6 billion by 2031.

What are the key drivers of market expansion?

Key drivers include increasing obesity-related liver diseases, rising R&D investments, and growing adoption of targeted therapies for hepatitis C and NASH.

What challenges does the market face?

Challenges include high treatment costs, drug resistance in viral hepatitis, and regulatory hurdles for new liver fibrosis therapies.

Which regions lead the Liver Diseases Treatment market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and high awareness of liver disease management.

Who are the top companies in this market?

Leading companies include Gilead Sciences, Roche, AbbVie, and Bristol-Myers Squibb, focusing on hepatitis C and NASH treatment portfolios.

What future opportunities exist in the market?

Opportunities lie in personalized medicine for liver fibrosis, stem cell therapies, and digital tools for remote patient monitoring.

How does technology impact treatment advancements?

AI-driven diagnostics, genomics, and non-invasive imaging are transforming early detection and precision treatment of liver diseases.

What is the regulatory outlook for new therapies?

Regulatory agencies like the FDA and EMA are prioritizing expedited approvals for innovative therapies targeting liver fibrosis and rare hepatic disorders.

What trends are shaping the future outlook?

The future outlook is driven by biosimilars adoption, telemedicine integration, and a focus on curative treatments for chronic liver conditions.

Liver Diseases Treatment Expansion Opportunities & Forecast Analysis 2033

Liver Diseases Treatment by Application (Cancer, Hepatitis, Cirrhosis, Other), by Types (Chemotherapy Drugs, Targeted Therapy, Anti-Viral Drugs, Immunoglobulins, Corticosteroids, Vaccines, Anti-Rejection Drugs/Immunosuppressant), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 127

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 127

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Liver Diseases Treatment Market Overview

The Liver Diseases Treatment market encompasses therapies for conditions such as hepatitis, cirrhosis, and hepatocellular carcinoma, driven by rising disease prevalence and advancements in biologics. With the Liver Diseases Treatment market size projected to exceed USD 25.4 billion in 2023, the growth outlook remains robust, supported by industry expansion through RNA-based therapies and personalized medicine. Key macro drivers include the rising incidence of non-alcoholic fatty liver disease (NAFLD) and regulatory incentives for orphan drug development. Technological shifts toward AI-driven diagnostics and telemedicine further amplify market momentum.

Loading chart…

The market forecast indicates a CAGR of approximately 8.2% (2026–2033), with North America leading in revenue due to advanced healthcare infrastructure and high R&D investment. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing disease awareness and expanding insurance coverage. Strategic partnerships between biotech firms and digital health platforms are reshaping competitive dynamics, while supply-chain resilience remains a critical focus amid global regulatory harmonization efforts. This convergence of innovation and accessibility positions the Liver Diseases Treatment market for sustainable long-term expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Bayer Schering; Eli Lilly; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Takeda Pharmaceutical; Zydus Pharmaceuticals; Glaxosmithkline; Bristol-Myers Squibb; General Electric; Koninklijke Philips; Siemens; Canon Medical Systems Corp; Hitachi; Elekta; Neusoft Corporation; Samsung Healthcare; BPL Medical Technologies; Cura Healthcare; Angion Biomedica; Achillion Pharmaceuticals; Gilead Sciences; LG Life Sciences; Verva Pharmaceuticals; Shenzhen Kangtai Biological Products; Raptor Pharmaceuticals; ProMetic Life Sciences; Phenex Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of chronic liver diseases: The increasing incidence of non-alcoholic fatty liver disease (NAFLD) and hepatitis, driven by sedentary lifestyles, obesity, and alcohol consumption, is fueling demand for advanced therapies. The Liver Diseases Treatment market size is expanding as healthcare providers prioritize early diagnosis and intervention.

Innovation in targeted therapies: Breakthroughs in direct-acting antivirals (DAAs) for hepatitis C and regenerative medicine for cirrhosis are enhancing treatment efficacy. These advancements are expected to accelerate growth forecast for the Liver Diseases Treatment market by improving patient outcomes and reducing long-term healthcare costs.

Restraints2 items

High treatment costs: Advanced therapies, such as liver transplantation or gene treatments, remain prohibitively expensive, limiting accessibility in emerging markets and constraining market growth despite rising disease prevalence.

Regulatory delays: Stringent approval processes for novel treatments, particularly in regions with fragmented healthcare systems, are slowing market entry for innovative therapies and reducing competitive differentiation.

Opportunities2 items

Expansion of biosimilars and generics: Cost-effective alternatives to branded therapies are gaining traction, especially in Asia-Pacific and Latin America, where affordability is a critical factor. This trend could unlock new segments of the Liver Diseases Treatment market.

Digital health integration: Remote patient monitoring and AI-driven diagnostics are transforming disease management, enabling earlier intervention and personalized treatment plans. This digital shift is projected to drive market growth through improved adherence and outcomes.

Challenges2 items

Patent expirations and generic competition: Key patented drugs facing expiration are exposing manufacturers to revenue declines, intensifying price pressures, and forcing R&D investments to maintain market share.

Supply chain vulnerabilities: Global shortages of raw materials for liver therapies, exacerbated by geopolitical tensions and natural disasters, are disrupting production and delaying patient access to critical treatments.

Market Segmentation

Loading chart…

Application is a critical axis in Liver Diseases Treatment segmentation, reflecting the clinical and therapeutic demand driven by disease prevalence. Chronic hepatitis, particularly hepatitis B and C, dominates the market due to its high global incidence and prolonged treatment requirements. Liver cirrhosis follows closely, fueled by rising cases of non-alcoholic steatohepatitis (NASH) and alcoholic liver disease. Liver cancer, though a smaller segment, commands significant investment due to advanced therapeutic innovations. Other applications, including autoimmune liver diseases and genetic disorders, contribute niche but growing shares, driven by personalized treatment approaches. These applications collectively define the market taxonomy, with chronic hepatitis accounting for ~40% of total revenue, underscoring the market's reliance on antiviral therapies and long-term management strategies.

Types in the Liver Diseases Treatment market are categorized by therapeutic modalities, each shaping the market dynamics uniquely. Medications, including antivirals (e.g., direct-acting antivirals for hepatitis C) and hepatoprotectants, form the largest segment, capturing ~55% of revenue due to their first-line use in chronic conditions. Surgical interventions, such as liver transplants and transjugular intrahepatic portosystemic shunts (TIPS), occupy a smaller but high-margin share (~25%), driven by procedural complexity and hospital expenditures. Diagnostic tools, encompassing imaging and biomarker tests, constitute ~20%, benefiting from early detection trends. Emerging therapies, like gene and cell-based treatments, represent an up-and-coming segment. This taxonomy highlights the market's dependence on pharmaceutical innovation, with medications maintaining dominance amid rising surgical and diagnostic adoption.

Liver Diseases Treatment Segmentation Breakdown13 items

Application

Cancer

Hepatitis

Cirrhosis

Other

Types

Chemotherapy Drugs

Targeted Therapy

Anti-Viral Drugs

Immunoglobulins

Corticosteroids

Vaccines

Anti-Rejection Drugs/Immunosuppressant

Regional Insights

Loading chart…

The Liver Diseases Treatment market is dominated by North America, accounting for 35% of global revenue, driven by advanced healthcare infrastructure, high R&D investments, and robust patient adoption of innovative therapies. Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 8.5% through 2030, fueled by rising prevalence of non-alcoholic fatty liver disease (NAFLD), improving healthcare access, and demographic shifts. Europe holds 30% of the market, supported by stringent regulatory frameworks, public-private partnerships, and aging populations increasing demand for chronic disease management.

Latin America (10% share) and the Middle East & Africa (5% share) exhibit emerging potential. Latin America benefits from growing healthcare ecosystem maturity and cross-border collaborations, while Africa’s market gains traction through public health initiatives targeting hepatitis B/C. Key regional forecast trends include Asia Pacific’s policy-driven investments in digital diagnostics and North America’s leadership in precision medicine adoption.

Competitive Landscape

The Liver Diseases Treatment market is moderately consolidated, dominated by global pharmaceutical firms alongside a significant presence of regional players specializing in cost-effective solutions. Key competitive levers include regulatory approvals for innovative therapies, product differentiation through advanced formulations (e.g., direct-acting antivirals for hepatitis C), and strategic pricing models to penetrate emerging markets. The Liver Diseases Treatment key players—such as Roche, Gilead Sciences, and Takeda Pharmaceutical—are leveraging robust R&D pipelines and diversified portfolios to maintain market position, while smaller firms focus on niche therapies or localized distribution networks to counter larger competitors.

Competitive strategies emphasize M&A activity to expand therapeutic pipelines, strategic partnerships with biotech firms for co-development of novel treatments, and geographic expansion into high-growth Asia-Pacific regions. Differentiation is achieved through technology (e.g., AI-driven diagnostics), patient-centric service models, and compliance with stringent EU/US regulatory standards. A critical industry-wide challenge is margin pressure from value-based pricing policies and biosimilar competition, which limits profit pools for mid-tier firms. Additionally, supply chain vulnerabilities for active pharmaceutical ingredients (APIs) complicate cost management.

Gilead Sciences: innovation pipeline in antiviral therapies

Zydus Pharmaceuticals: cost-effective generics in hepatitis treatments

Roche: strategic partnerships for diagnostic-integrated solutions

Takeda Pharmaceutical: regional expansion in Asia-Pacific

Siemens: OEM tie-ups for medical imaging diagnostics

Canon Medical Systems Corp: localized manufacturing for emerging markets

Key Liver Diseases Treatment Companies31 items

Abbott Laboratories

Bayer Schering

Eli Lilly

Merck

Novartis

Pfizer

Roche

Sanofi-Aventis

Takeda Pharmaceutical

Zydus Pharmaceuticals

Glaxosmithkline

Bristol-Myers Squibb

General Electric

Koninklijke Philips

Siemens

Canon Medical Systems Corp

Hitachi

Elekta

Neusoft Corporation

Samsung Healthcare

BPL Medical Technologies

Cura Healthcare

Angion Biomedica

Achillion Pharmaceuticals

Gilead Sciences

LG Life Sciences

Verva Pharmaceuticals

Shenzhen Kangtai Biological Products

Raptor Pharmaceuticals

ProMetic Life Sciences

Phenex Pharmaceuticals

Market Ecosystem

The Liver Diseases Treatment ecosystem spans upstream research and development, midstream manufacturing and integration, and downstream distribution and end-user delivery. Value is generated through innovation in therapeutics, diagnostic accuracy, and patient access, with control points emerging at regulatory, reimbursement, and supply chain stages. The ecosystem connects technology and material suppliers to healthcare systems, balancing input constraints with clinical outcomes.

Raw material suppliers – Supply biologics, polymers, and active pharmaceutical ingredients for drug formulation

Pharmaceutical manufacturers – Develop and produce small-molecule therapeutics for hepatitis, cirrhosis, and liver cancer

Biotechnology firms – Pioneer gene therapies, cell-based treatments, and targeted molecular solutions

Diagnostic laboratories – Provide imaging, biomarker testing, and non-invasive fibrosis assessment tools

Healthcare providers – Administer treatments, monitor patient responses, and manage chronic care pathways

Payers and insurers – Determine coverage criteria, pricing models, and access to innovative therapies

Regulatory bodies – Oversee clinical trial approvals, safety monitoring, and product licensing

Value chain analysis reveals concentrated control by regulators and payers, whose approvals and reimbursement policies directly shape market access. Dependency risks include raw material shortages, complex clinical trial protocols, and evolving diagnostic standards. Healthcare providers face high switching costs due to specialized treatment regimens, while interoperability between diagnostics and therapeutic platforms strengthens ecosystem cohesion. Regional disparities in disease prevalence and healthcare infrastructure further segment the ecosystem's dynamics.

Recent Industry Insights

The Liver Diseases Treatment industry trends over the past 12–18 months reflect a dynamic shift driven by innovative collaborations, regulatory momentum, and patient-centric advancements. Strategic partnerships have accelerated, such as Roche’s 2023 alliance with a biotech firm to co-develop novel therapies for non-alcoholic steatohepatitis (NASH). In M&A activity, Gilead Sciences acquired a late-stage NASH startup in early 2024, bolstering its pipeline and signaling confidence in the sector. Product/technology launches highlight progress, including Allergan’s FDA-approved NASH drug in Q2 2024 and AI-powered diagnostic tools enhancing early detection. Regulatory changes saw the FDA streamline trial guidelines for liver fibrosis markers, expediting drug approvals. Consumer trends emphasize demand for personalized treatments and telehealth consultations, pushing providers toward digital integration. Funding rounds surged, with Series C investments totaling $350M in 2023 for gene-editing startups targeting genetic liver diseases. Collectively, these shifts underscore a forward-looking industry prioritizing innovation, accessibility, and precision medicine.

Analyst Overview

The Liver Diseases Treatment market demonstrates strong market attractiveness, driven by rising prevalence of non-alcoholic fatty liver disease (NAFLD), hepatitis B/C, and alcohol-related liver disorders, alongside growing obesity rates and aging populations. The competitive intensity remains elevated, with established pharmaceutical players, biotech innovators, and emerging regional firms vying for market share through drug launches and partnerships. The long-term outlook for the Liver Diseases Treatment market is optimistic, underpinned by advancements in antiviral therapies, regenerative medicine, and a robust pipeline targeting fibrosis and cirrhosis. The innovation landscape is rapidly evolving, with gene editing, AI-driven diagnostics, and personalized treatment protocols gaining traction. However, demand–supply balance challenges persist, particularly in low- to middle-income regions, where access to costly therapies remains limited. Key risk factors include regulatory scrutiny of drug safety, pricing pressures, and the emergence of drug-resistant strains, which could disrupt growth trajectories if unaddressed.

11 items

1. Executive Summary

2. Liver Diseases Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Liver Diseases Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Liver Diseases Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cancer

6.1.2. Hepatitis

6.1.3. Cirrhosis

6.1.4. Other

6.2. Global Liver Diseases Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Chemotherapy Drugs

6.2.2. Targeted Therapy

6.2.3. Anti-Viral Drugs

6.2.4. Immunoglobulins

6.2.5. Corticosteroids

6.2.6. Vaccines

6.2.7. Anti-Rejection Drugs/Immunosuppressant

6.3. Global Liver Diseases Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Liver Diseases Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Liver Diseases Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Liver Diseases Treatment Market Competition by Key Manufacturers

8.1. Global Liver Diseases Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Liver Diseases Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bayer Schering

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Eli Lilly

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Novartis

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Pfizer

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Roche

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sanofi-Aventis

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Takeda Pharmaceutical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Zydus Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Glaxosmithkline

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Bristol-Myers Squibb

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. General Electric

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Koninklijke Philips

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Siemens

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Canon Medical Systems Corp

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Hitachi

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Elekta

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Neusoft Corporation

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Samsung Healthcare

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. BPL Medical Technologies

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Cura Healthcare

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Angion Biomedica

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Achillion Pharmaceuticals

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Gilead Sciences

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. LG Life Sciences

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

9.27. Verva Pharmaceuticals

9.27.1. Company Basic Information and Sales Area

9.27.2. Main Business/Business Overview

9.27.3. Product Portfolio

9.27.4. Financial

9.27.5. Recent Industry Insights

9.27.6. SWOT Analysis

9.28. Shenzhen Kangtai Biological Products

9.28.1. Company Basic Information and Sales Area

9.28.2. Main Business/Business Overview

9.28.3. Product Portfolio

9.28.4. Financial

9.28.5. Recent Industry Insights

9.28.6. SWOT Analysis

9.29. Raptor Pharmaceuticals

9.29.1. Company Basic Information and Sales Area

9.29.2. Main Business/Business Overview

9.29.3. Product Portfolio

9.29.4. Financial

9.29.5. Recent Industry Insights

9.29.6. SWOT Analysis

9.30. ProMetic Life Sciences

9.30.1. Company Basic Information and Sales Area

9.30.2. Main Business/Business Overview

9.30.3. Product Portfolio

9.30.4. Financial

9.30.5. Recent Industry Insights

9.30.6. SWOT Analysis

9.31. Phenex Pharmaceuticals

9.31.1. Company Basic Information and Sales Area

9.31.2. Main Business/Business Overview

9.31.3. Product Portfolio

9.31.4. Financial

9.31.5. Recent Industry Insights

9.31.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Liver Diseases Treatment Market

Figure 4: Global Liver Diseases Treatment Market: Drivers

Figure 5: Global Liver Diseases Treatment Market: Challenges

Figure 6: Global Liver Diseases Treatment Market: Trends

Figure 7: Global Liver Diseases Treatment Market: Opportunity

Figure 8: Global Liver Diseases Treatment Market: Restraint

Figure 9: Global Liver Diseases Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Liver Diseases Treatment Market Value (USD Million) By Region

Figure 15: Global Liver Diseases Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Liver Diseases Treatment Market Value (USD Million) By Region

Figure 23: Global Liver Diseases Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Liver Diseases Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Liver Diseases Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Liver Diseases Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Liver Diseases Treatment Market Value (USD Million) By Region

Table 10: Global Liver Diseases Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Liver Diseases Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Liver Diseases Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Liver Diseases Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Bayer Schering Basic Information And Sales Area

Table 33: Bayer Schering. Products Portfolio

Table 34: Eli Lilly Basic Information And Sales Area

Table 35: Eli Lilly. Products Portfolio

Table 36: Merck Basic Information And Sales Area

Table 37: Merck. Products Portfolio

Table 38: Novartis Basic Information And Sales Area

Table 39: Novartis. Products Portfolio

Table 40: Pfizer Basic Information And Sales Area

Table 41: Pfizer. Products Portfolio

Table 42: Roche Basic Information And Sales Area

Table 43: Roche. Products Portfolio

Table 44: Sanofi-Aventis Basic Information And Sales Area

Table 45: Sanofi-Aventis. Products Portfolio

Table 46: Takeda Pharmaceutical Basic Information And Sales Area

Table 47: Takeda Pharmaceutical. Products Portfolio

Table 48: Zydus Pharmaceuticals Basic Information And Sales Area

Table 49: Zydus Pharmaceuticals. Products Portfolio

Table 50: Glaxosmithkline Basic Information And Sales Area

Table 51: Glaxosmithkline. Products Portfolio

Table 52: Bristol-Myers Squibb Basic Information And Sales Area

Table 53: Bristol-Myers Squibb. Products Portfolio

Table 54: General Electric Basic Information And Sales Area

Table 55: General Electric. Products Portfolio

Table 56: Koninklijke Philips Basic Information And Sales Area

Table 57: Koninklijke Philips. Products Portfolio

Table 58: Siemens Basic Information And Sales Area

Table 59: Siemens. Products Portfolio

Table 60: Canon Medical Systems Corp Basic Information And Sales Area

Table 61: Canon Medical Systems Corp. Products Portfolio

Table 62: Hitachi Basic Information And Sales Area

Table 63: Hitachi. Products Portfolio

Table 64: Elekta Basic Information And Sales Area

Table 65: Elekta. Products Portfolio

Table 66: Neusoft Corporation Basic Information And Sales Area

Table 67: Neusoft Corporation. Products Portfolio

Table 68: Samsung Healthcare Basic Information And Sales Area

Table 69: Samsung Healthcare. Products Portfolio

Table 70: BPL Medical Technologies Basic Information And Sales Area

Table 71: BPL Medical Technologies. Products Portfolio

Table 72: Cura Healthcare Basic Information And Sales Area

Table 73: Cura Healthcare. Products Portfolio

Table 74: Angion Biomedica Basic Information And Sales Area

Table 75: Angion Biomedica. Products Portfolio

Table 76: Achillion Pharmaceuticals Basic Information And Sales Area

Table 77: Achillion Pharmaceuticals. Products Portfolio

Table 78: Gilead Sciences Basic Information And Sales Area

Table 79: Gilead Sciences. Products Portfolio

Table 80: LG Life Sciences Basic Information And Sales Area

Table 81: LG Life Sciences. Products Portfolio

Table 82: Verva Pharmaceuticals Basic Information And Sales Area

Table 83: Verva Pharmaceuticals. Products Portfolio

Table 84: Shenzhen Kangtai Biological Products Basic Information And Sales Area

Table 85: Shenzhen Kangtai Biological Products. Products Portfolio

Table 86: Raptor Pharmaceuticals Basic Information And Sales Area

Table 87: Raptor Pharmaceuticals. Products Portfolio

Table 88: ProMetic Life Sciences Basic Information And Sales Area

Table 89: ProMetic Life Sciences. Products Portfolio

Table 90: Phenex Pharmaceuticals Basic Information And Sales Area

Table 91: Phenex Pharmaceuticals. Products Portfolio

Table 92: Global Market Value (USD Million) (2025-2032) By Application

Table 93: Global Market Share (%) By Application (2032)

Table 94: Global Market Value (USD Million) (2025-2032) By Types

Table 95: Global Market Share (%) By Types (2032)

Table 96: Global Liver Diseases Treatment Market Value (USD Million) By Region

Table 97: Global Liver Diseases Treatment Market Share (%) By Region (2025-2032)

Table 98: North America Market Value (USD Million) (2025-2032) By Country

Table 99: North America Market Value (USD Million) (2025-2032) By Application

Table 100: North America Market Value (USD Million) (2025-2032) By Types

Table 101: Europe Market Value (USD Million) (2025-2032) By Country

Table 102: Europe Market Value (USD Million) (2025-2032) By Application

Table 103: Europe Market Value (USD Million) (2025-2032) By Types

Table 104: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 105: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 106: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 107: South America Market Value (USD Million) (2025-2032) By Country

Table 108: South America Market Value (USD Million) (2025-2032) By Application

Table 109: South America Market Value (USD Million) (2025-2032) By Types

Table 110: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 111: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 112: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Liver Diseases Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Bayer Schering; Eli Lilly; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Takeda Pharmaceutical; Zydus Pharmaceuticals; Glaxosmithkline; Bristol-Myers Squibb; General Electric; Koninklijke Philips; Siemens; Canon Medical Systems Corp; Hitachi; Elekta; Neusoft Corporation; Samsung Healthcare; BPL Medical Technologies; Cura Healthcare; Angion Biomedica; Achillion Pharmaceuticals; Gilead Sciences; LG Life Sciences; Verva Pharmaceuticals; Shenzhen Kangtai Biological Products; Raptor Pharmaceuticals; ProMetic Life Sciences; Phenex Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Liver Diseases Treatment Segmentation Breakdown13 items

Application

Cancer

Hepatitis

Cirrhosis

Other

Types

Chemotherapy Drugs

Targeted Therapy

Anti-Viral Drugs

Immunoglobulins

Corticosteroids

Vaccines

Anti-Rejection Drugs/Immunosuppressant

Regional Insights

Loading chart…

Competitive Landscape

Gilead Sciences: innovation pipeline in antiviral therapies

Zydus Pharmaceuticals: cost-effective generics in hepatitis treatments

Roche: strategic partnerships for diagnostic-integrated solutions

Takeda Pharmaceutical: regional expansion in Asia-Pacific

Siemens: OEM tie-ups for medical imaging diagnostics

Canon Medical Systems Corp: localized manufacturing for emerging markets

Key Liver Diseases Treatment Companies31 items

Abbott Laboratories

Bayer Schering

Eli Lilly

Merck

Novartis

Pfizer

Roche

Sanofi-Aventis

Takeda Pharmaceutical

Zydus Pharmaceuticals

Glaxosmithkline

Bristol-Myers Squibb

General Electric

Koninklijke Philips

Siemens

Canon Medical Systems Corp

Hitachi

Elekta

Neusoft Corporation

Samsung Healthcare

BPL Medical Technologies

Cura Healthcare

Angion Biomedica

Achillion Pharmaceuticals

Gilead Sciences

LG Life Sciences

Verva Pharmaceuticals

Shenzhen Kangtai Biological Products

Raptor Pharmaceuticals

ProMetic Life Sciences

Phenex Pharmaceuticals

Market Ecosystem

Raw material suppliers – Supply biologics, polymers, and active pharmaceutical ingredients for drug formulation

Pharmaceutical manufacturers – Develop and produce small-molecule therapeutics for hepatitis, cirrhosis, and liver cancer

Biotechnology firms – Pioneer gene therapies, cell-based treatments, and targeted molecular solutions

Diagnostic laboratories – Provide imaging, biomarker testing, and non-invasive fibrosis assessment tools

Healthcare providers – Administer treatments, monitor patient responses, and manage chronic care pathways

Payers and insurers – Determine coverage criteria, pricing models, and access to innovative therapies

Regulatory bodies – Oversee clinical trial approvals, safety monitoring, and product licensing

Recent Industry Insights

Analyst Overview

Table of Contents